$KPTI has been mentioned 4 times over the past 12 months by 2 distinct FinTwit voices, with @jacobplieth leading discussion with 3 mentions and @adamfeuerstein contributing 1 mention. The first mention in the archive dates to February 13, 2026, with the most recent activity on April 30, 2026. Biotech-focused voices have dominated the conversation around Karyopharm Therapeutics.

Discussion centered on the company's clinical trial data and conference presentation strategy. @jacobplieth raised questions about what information regarding the Sentry trial—including SVR35 numbers, TSS numbers, and OS numbers—was being reserved for an ASCO26 late-breaker presentation. @adamfeuerstein commented on selinexor's myelofibrosis Phase 3 trial results, noting the drug achieved the spleen reduction endpoint but missed on symptoms improvement measures.